VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 83 filers reported holding VAXCYTE INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,973,398 | +15.3% | 176,018 | +13.0% | 0.01% | +33.3% |
| Q2 2023 | $7,779,553 | +385.1% | 155,778 | +264.1% | 0.01% | +350.0% |
| Q1 2023 | $1,603,732 | -21.8% | 42,789 | 0.0% | 0.00% | -33.3% |
| Q4 2022 | $2,051,732 | +314.7% | 42,789 | +107.5% | 0.00% | +200.0% |
| Q3 2022 | $494,808 | +15.1% | 20,617 | +4.3% | 0.00% | 0.0% |
| Q2 2022 | $430,000 | +11.1% | 19,759 | +23.3% | 0.00% | 0.0% |
| Q1 2022 | $387,000 | +1.6% | 16,021 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $381,000 | -4.3% | 16,021 | +2.0% | 0.00% | 0.0% |
| Q3 2021 | $398,000 | +12.7% | 15,700 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $353,000 | +46.5% | 15,700 | +28.4% | 0.00% | – |
| Q1 2021 | $241,000 | +17.6% | 12,226 | +58.8% | 0.00% | – |
| Q4 2020 | $205,000 | -29.1% | 7,698 | +31.5% | 0.00% | -100.0% |
| Q3 2020 | $289,000 | -95.6% | 5,853 | -97.2% | 0.00% | -93.3% |
| Q2 2020 | $6,522,000 | – | 206,322 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |